Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib with Pemetrexed/Cisplatin in Advanced Nonsquamous NSCLC
NCT02119650Phase 2Terminated
- Sponsor
- Incyte
- Start
- Feb 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in non-small cell lung cancer (NSCLC), sponsored by Incyte. Started Feb 2014; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02119650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02119650.